17 results about "HPV vaccines" patented technology

The invention relates to a method for detecting the in vitro relative potency of a type 9 HPV vaccine or antigen stock solution. Specifically, the in vitro relative potency of an HPV-VLP antigen stock solution and vaccine finished products (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) is detected by using an enzyme-linked immunosorbent assay. The enzyme-linked immunosorbent assay has excellent accuracy and precision, the standardization level of HPV vaccine quality evaluation is improved, and a foundation is expected to be laid for promoting research and development of high-quality HPV vaccines.

The invention discloses a PVX expression vector pWX for efficiently expressing foreign protein and application of the PVX expression vector pWX. In the construction process of optimizing potato X virus infectious clone, after a single base mutation NruI-gene sequence (CCGCGA) is inserted into an upstream regulation region of a PVX coat protein subgene promoter, a novel PVX expression vector capable of promoting foreign protein expression is obtained, and the novel PVX expression vector is named as pWX. Experiments prove that compared with a control vector, the accumulation amount of GFP (Green Fluorescent Protein) generated by the pWX vector through transient expression of agrobacterium in tobacco is obviously increased. The invention further applies a pWX vector to successfully express an important target protein HPV16L1 researched and developed by an HPV vaccine, and the expression quantity of the important target protein HPV16L1 in tobacco is 5.25 micrograms per gram of fresh heavy leaves. The invention provides a novel vector based on a PVX genome for high-efficiency expression of a plant source target protein, and the vector has a good application prospect in preparation of plant source vaccines.

This invention relates to a homogeneous photocatalytic chemiluminescence detection system for detecting HPV vaccine antigen content, its preparation method, and its application. The system utilizes self-made carboxyl-modified donor microspheres and receptor microspheres, coupled with HPV type-specific monoclonal antibodies via EDC / NHS activation, achieving one-step homogeneous detection. By optimizing the microsphere size, a 200 nm microsphere system was found to exhibit higher luminescence signal, a wider detection range, and better sensitivity when detecting HPV16 / 18 VLPs. This method is simple to operate, requires no plate washing, and possesses good specificity, accuracy, and precision. It is suitable for the in vitro relative potency and identification detection of bivalent HPV vaccines, and can replace traditional ELISA methods, reducing detection costs and safety risks. It is also suitable for large-scale applications in vaccine quality control.

The present application relates to the application of enzyme-linked immunoassay for detecting the in vitro relative potency of HPV-VLP antigen stock solution and vaccine finished product (types 6, 11, 16 and 18). The enzyme-linked immunoassay of the present application has universality for detecting antigens produced by different expression systems (Hansenula, Pichia, Escherichia coli and insect cells), and improves the standardization level of HPV vaccine quality evaluation, and lays a foundation for promoting the research and development of high-quality HPV vaccine.

The present application relates to a method for detecting the in vitro relative potency of HPV-9 vaccine or antigen stock solution, and specifically applying enzyme-linked immunoassay to detect the in vitro relative potency of HPV-VLP antigen stock solution and vaccine finished product (types 6, 11, 16, 18, 31, 33, 45, 52 and 58). The enzyme-linked immunoassay of the present application has excellent accuracy and precision, improves the standardization level of HPV vaccine quality evaluation, and is expected to lay a foundation for promoting the research and development of high-quality HPV vaccine.

The present invention relates to a vaccine for use in therapeutic vaccination of a human subject against a human papillomavirus 16 (HPV16)-related virus, wherein said vaccine provides at least five discrete immunization peptides consisting of amino acid sequences selected from at least five of the following groups: (i) SEQ ID NOs: 1 to 10; (ii) SEQ ID NOs: 11 to 52; (iii) SEQ ID NOs:53 to 79; (iv) SEQ ID NOs: 71 and 80 to 96; (v) SEQ ID NOs:25, 81, and 97-106; and (vi) SEQ ID NOs: 9, 12, 23, 63, 81, 85, 101, and 107 to 131; wherein said vaccine is a human leukocyte antigen (HLA) universal vaccine for use in any human subject expressing at least one HLA of a HLA supertype selected from the list consisting of HLA-A01, HLA-A02, HLA-A03 / A11, HLA-A24, HLA- B07, and HLA-B15, and wherein each of said at least five immunization peptides, when presented as an H LA-complex, activates human anti-immunization peptide T cells. The present invention also relates to kits, devices, and methods related thereto.

The invention provides an anti-HPV45L1 protein monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The monoclonal antibodies 15D4 and 17F9 provided by the invention can be specifically combined with the 45 subtype of HPV, have the characteristics of neutralizing the HPV59 pseudovirus and blocking the infection of the HPV59 pseudovirus, and can be used for detecting the HPV45 antigen. Meanwhile, the epitopes recognized by the two monoclonal antibodies are epitopes targeted by dominant neutralizing antibodies in serum after vaccine immunization, so that the epitopes can be used for antigen detection and can also be directly used for evaluating the neutralizing antibody generation capability induced by the HPV vaccine. The invention further provides a double-antibody sandwich ELISA kit, the kit can specifically recognize and quantify the HPV45LI protein with complete conformation and immunogenicity in a sample, the kit can be stably produced in batch, rapid evaluation of the in-vitro activity of the HPV vaccine is achieved, and the kit has a good application prospect.

The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

The invention belongs to the technical field of biological medicines, and particularly relates to a method for preparing a pentamer by taking HPV-VLPs as a substrate. The invention provides a method for preparing a pentamer by taking HPV-VLPs expressed by an eukaryotic expression system as a substrate, the method is simple and efficient, and a thought is provided for an eukaryotic expression route process and a verification method; the eukaryotic pentamer prepared by the method provides a key material for carrying out eukaryotic pentamer research and developing HPV vaccines.

Provided are an HPV vaccine containing a nucleic acid molecule encoding an HPV antigen and an immune costimulatory factor, and the use thereof.

The invention provides a fusion gene and an HPV nucleic acid vaccine. A fusion gene is obtained through research and optimization, and the fusion gene is obtained by sequentially connecting an L1 gene of an HPV 16 type, an E5 gene, an E6 gene and an E7 gene of the HPV 16 type and an E5 gene, an E6 gene and an E7 gene of an HPV 52 type. The inventor finds that an HPV vaccine prepared by taking the fusion gene as an antigen component can effectively promote cellular immune response and formation of long-term protective memory, promote hair growth center response and formation of humoral immune memory, remarkably improve the proportion of NKT cells, successfully activate systemic anti-tumor cell immune response of mice, and improve the anti-tumor effect of the mice. The anti-tumor immune effect is greatly improved. The traditional Chinese medicine composition has the dual effects of prevention and treatment, has the prevention capability, can effectively inhibit tumor growth and has the tumor treatment capability. The HPV vaccine also has the advantages of high safety, good stability and the like, and has a wide application prospect.

The invention provides an anti-HPV59L1 protein monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The monoclonal antibodies 13E1 and 23E11 provided by the invention can be specifically combined with the HPV59 subtype, have the characteristics of neutralizing the HPV59 pseudovirus and blocking the infection of the HPV59 pseudovirus, and can be used for detecting the HPV59 antigen. Wherein the epitope recognized by 13E1 is the epitope targeted by a dominant neutralizing antibody in serum after vaccine immunization, so that the epitope not only can be used for antigen detection, but also can be directly used for evaluating the neutralizing antibody generation capability induced by the HPV vaccine. The invention further provides a double-antibody sandwich ELISA kit, the kit can specifically recognize and quantitatively detect the HPV59LI protein which is complete in conformation and has immunogenicity in a sample, the kit can be stably produced in batch, rapid evaluation of the in-vitro activity of the HPV vaccine can be achieved, and the kit has a good application prospect.

The invention discloses a quantitative detection method for an IgG antibody generated by an HPV vaccine, which comprises the following steps: firstly preparing and marking a capture reagent, then preparing a standard curve sample, a quality control sample, a detection antibody and a sample to be detected, and finally determining the IgG amount of the sample to be detected based on an ELISA (Enzyme-Linked Immunosorbent Assay) method. Through a Luminex platform or a U-PLEX MSD platform based on the ELISA technology, multiple IgG antibody types can be quantitatively tested at the same time, and high-throughput detection can be achieved.

The present invention relates to a vaccine against a human papillomavirus 16 (HPV16)-related virus providing at least six discrete immunization peptides consisting of the amino acid sequences of SEQ ID NOs:1 to 6, wherein said vaccine comprises a mixture of discrete peptides each comprising exactly one of said amino acid sequences; and to the vaccine for use in medicine and in eliciting an immune response in a human subject against HPV infection, as well as a kit related thereto.

The invention relates to a HPV vaccine composition and a dengue vaccine composition for use in a method of preventing an HPV-associated disease and dengue disease in a subject or in a subject population, the method comprising concomitantly administering the HPV vaccine composition and the dengue vaccine composition, wherein the dengue vaccine composition is a tetravalent dengue composition comprising live, attenuated DENV-1, DENV-2, DENV-3 and DENV-4 strains and wherein the method provides combined vaccine efficacy against all four serotypes of the dengue virus and non-inferiority of the immune respone to the HPV vaccine composition compared to a mono-administratrion of the HPV vaccine composition.